10X GENOMICS, INC. Funds and ETFs 10x Genomics, Inc.
Equities
TXG
US88025U1097
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.58 USD | -0.79% |
|
-10.45% | -50.71% |
| Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
| Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
ETFs positioned on 10x Genomics, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.34% | 16 M€ | -7.93% | ||
| 1.26% | 1 M€ | 0.00% | - | |
| 1.16% | 1 M€ | 0.00% | - | |
| 0.76% | 2 M€ | -.--% | ||
| 0.35% | 5 M€ | -1.80% | - | |
| 0.31% | 18 M€ | +4.14% | - | |
| 0.30% | 0 M€ | 0.00% | - | |
| 0.27% | 7 M€ | -.--% | - | |
| 0.26% | 0 M€ | 0.00% | - | |
| 0.11% | 115 M€ | +5.89% | - | |
| 0.07% | 773 M€ | -.--% | - | |
| 0.05% | 9 M€ | -.--% | - | |
| 0.01% | 2,658 M€ | +9.62% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 15.26% | 215 M€ | +11.92% | - |
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Calendar
2024-04-30
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.8
USD
Average target price
52.29
USD
Spread / Average Target
+88.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.71% | 3.31B | |
| +0.80% | 12.66B | |
| -12.75% | 7.04B | |
| +2.81% | 5.39B | |
| -1.37% | 4.45B | |
| +3.89% | 4.32B | |
| +9.29% | 2.6B | |
| -15.10% | 2.01B | |
| -2.82% | 1.67B | |
| -14.72% | 1.65B |
- Stock Market
- Equities
- TXG Stock
- Funds and ETFs 10x Genomics, Inc.
